Today's Trend
DENTSPLY SIRONA Inc. (NASDAQ: XRAY) appears to be getting a mixed but slightly constructive reaction from recent analyst updates. The stock has been moving higher overall, helped by a modest increase in near-term earnings expectations from Zacks Research and a recent presentation at a healthcare conference, though the analyst firm still keeps a Hold rating.
- Zacks Research raised its Q4 2026 EPS estimate for DENTSPLY SIRONA to $0.41 from $0.38, and also nudged its Q3 2026 forecast higher to $0.37 from $0.36, suggesting somewhat better profitability expectations ahead.
- The company presented at the Stifel Jaws & Paws Conference 2026, which may have drawn investor attention but did not include any clearly reported new guidance or material business update. Article Title
- Zacks Research left its overall view at Hold, signaling that analysts are not turning decisively bullish despite the improved short-term numbers.
- The same research firm lowered several forward EPS estimates, including FY2026 to $1.41 from $1.43, FY2027 to $1.51 from $1.56, and FY2028 to $1.65 from $1.73, which suggests some longer-term caution.
- Reported short interest was listed at 0 shares, so there is no meaningful short-interest signal available to influence trading.
Overall, XRAY’s move looks driven more by incrementally better near-term earnings expectations than by any major fundamental catalyst, while the lowered longer-term estimates keep the outlook somewhat mixed.